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A high number of nevi is the most significant phenotypic risk factor for melanoma and is in part genetically determined. The
number of nevi decreases from middle age onward but this senescence can be delayed in patients with melanoma. We investi-
gated the effects of nevus number count on sentinel node status and melanoma survival in a large cohort of melanoma cases.
Out of 2,184 melanoma cases, 684 (31.3%) had a high nevus count (>50). High nevus counts were associated with favorable
prognostic factors such as lower Breslow thickness, less ulceration and lower mitotic rate, despite adjustment for age. Nevus
count was not predictive of sentinel node status. The crude 5- and 10-year melanoma-specific survival rate was higher in mel-
anomas cases with a high nevus count compared to those with a low nevus count (91.2 vs. 86.4% and 87.2 vs. 79%, respec-
tively). The difference in survival remained significant after adjusting for all known melanoma prognostic factors (hazard ratio
[HR]50.43, confidence interval [CI]50.21–0.89). The favorable prognostic value of a high nevus count was also seen within
the positive sentinel node subgroup of patients (HR50.22, CI50.08–0.60). High nevus count is associated with a better mel-
anoma survival, even in the subgroup of patients with positive sentinel lymph node. This suggests a different biological
behavior of melanoma tumors in patients with an excess of nevi.
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The mean total body nevus count remains the most powerful
predictive phenotypic marker for melanoma risk.1–5 Nevi typ-
ically involute after the fourth decade of life in Caucasian
populations, and is attributed to a process of senescence.6
Nevi are therefore much less numerous in the elderly.2,7 The
rate at which nevi disappear with age varies greatly, with
some individuals having a large number of nevi in late mid-
dle life and this is associated with an increased risk of mela-
noma.8 This implied delayed senescence of nevi may result
from loss of tumor suppressor genes such as CDKN2A as
increased numbers of nevi occur in the carriers of germline
CDKN2A mutations and mutation in oncogenes such as
BRAF.9 Other studies have suggested that the telomere unit
could also play a role in the delayed nevus senescence
observed in patients with melanoma .10,11 High nevus count
has been reported to be associated with longer white cell telo-
meres as well as increased melanoma risk.6,12–14 Inherited
polymorphisms in genes determining telomere length are
associated with increased melanoma risk.9,15–20 The aim of
our study was to investigate whether nevus numbers are pre-
dictive of sentinel lymph node (SLN) status and melanoma
survival.
Material and Methods
For this retrospective study, we analyzed data from two dif-
ferent European Countries namely, Spain and United King-
dom. In Leeds (United Kingdom), case–control study, the
melanoma cases predominantly derived from a population
ascertained series recruited between 2000 and 2005.21 In
total, 960 cases were recruited as part of a case–control of
melanoma in Yorkshire, UK. The remaining 83 further mela-
noma cases were recruited from other centers on the basis of
presenting with a primary melanoma in sun-protected sites
to increase the numbers of these rare subtypes. In Valencia,
prospective melanoma cases, seen between January 2004 and
July 2013, were all included in the melanoma database of the
dermatology department of the Instituto Valenciano de
Oncologia (N5 463). The characteristics of this database
have been described in detail elsewhere.22 For Barcelona, mel-
anoma cases submitted to SLN biopsy were collected from
the Melanoma Unit at the Hospital Clinic of Barcelona
between October 1996 and 2013 and were recruited from
Catalonia as well as further a field as the melanoma clinic at
the Hospital Clinic Barcelona is a secondary and tertiary
referral center (N5 678). The Barcelona cohort has been
previously described in several studies.23–25
In situ melanoma, noncutaneous melanomas, patients
with unknown primaries or without follow-up were excluded.
For patients with multiple melanomas, the most invasive
melanoma tumor was included as it is the one that drives the
prognosis as reported earlier.26 Ulceration was defined
according to the AJCC criteria as the absence of intact epi-
dermis over a portion of the primary tumor. The nevus
counts were performed by dermatologists (for Valencia and
Barcelona, Spain) or trained research nurses (for Leeds,
United Kingdom).
All nevus count were performed at the time of the diagno-
sis of melanoma. The nevus counts in Barcelona were total
body nevus counts with linear data. For United Kingdom,
the nevus count protocol was also total body nevus counts
divided in 17 body parts. The total body nevus counts in the
Valencia cohort were using the cutoff values of 25, 50 and
100. Therefore, the data were not linear. To standardize the
nevus counts for our study, a cutoff of 50 nevi was used to
create two groups of high and low nevus counts (>50 nevi
larger than 2 mm in diameter vs. 50). SLN biopsy was per-
formed according to the guidelines for each institution and
the lymph nodes examined according to the standardized
protocol of European Organisation for Research and Treat-
ment of Cancer (EORTC). Ethics committee approval was
granted for each institution: the ethical committee of the
Hospital Clinic of Barcelona, the Leeds University ethics
committee application MREC 01/3/057 and for Valencia, the
ethics committee approval: Protocol # 2009-042.
Statistical Analyses
Pearson’s v2d and Student’s t-tests were used to compare the
categorical and continuous variables, respectively. For varia-
bles not normally distributed (e.g., Breslow thickness), the
values were log transformed for parametric testing. Logistic
regression was used to analyze the association between the
prognostic factors and the two nevus categories using a cutoff
of 50 nevi as well as the association between prognostic fac-
tors and SLN status as a binary valuable. Disease-specific sur-
vival (DSS) was calculated from the surgical excision date of
the primary melanoma to the date of melanoma death or last
checkup. A melanoma-related death is considered as a death
caused by systemic progression of disease in vital sites (brain,
visceral involvement) The exact date and cause of death were
checked in the Leeds cohort by registry data, annual patient
questionnaires, clinical notes and surveys of their primary
care physicians; in the Barcelona cohort by digital records of
What’s new?
Having a lot of pigmented skin lesions known as naevi or moles is a known risk factor for melanoma, but is it also a bad
prognostic marker for melanoma patients? The authors looked at the impact of nevus counts on melanoma survival in more
than 2000 patients and found the opposite: high nevus counts were associated with favorable prognostic markers and a
higher 5- and 10-year survival rate. These findings point to biological factor associated with high nevus count that may confer
improved survival and may be exploited therapeutically in the future.
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hospitals in Catalonia, shared digital records in Catalonia,
national registry data and telephone calls to relatives and in
Valencia via hospital registries, National Mortality Registry
and telephone calls to relatives.
Kaplan–Meier tables were used to calculate the estimated
5- and 10-year DSS. A Cox regression model was used to cal-
culate crude and adjusted hazard rations (HRs) and 95% con-
fidence intervals (CIs) for high nevus count compared to low
nevus count, censoring cases that were lost to follow up and
cases with nonmelanoma-related cause of death. The tests
based on Sch€oenfeld residuals and graphical methods using
Kaplan–Meier curves showed no evidence that the propor-
tional hazards assumption was violated for nevus count.
Models were adjusted for the “country source” to take in to
consideration the risk of possible bias in collecting data from
three centers. Other variables for adjustments were sex, age,
mitoses, Breslow thickness, ulceration, site of primary and
SLN status (positive vs. negative). Akaike information crite-
rion was used for the selection of model. All statistical tests
were two sided. The p-values of <0.05 were considered sig-
nificant. All data available for the descriptive statistics were
used but in the Cox multivariable model the sample size
drops to N5 724 because of missing data. Information on
SLN status had to be available to be included in the Cox
model were available. Statistical analyses were performed
using Stata/SE12.0 Statistical Software (STATA, College
Station, TX).
Results
Study population
A cohort of 2,184 melanoma cases from three European
studies was analyzed. From Leeds (United Kingdom) 1,043
(47.76%) melanoma cases recruited to a case–control study
were included for which detailed nevus count data were
available: 960 of these were population ascertained cases
recruited from the Yorkshire region (United Kingdm) and
were diagnosed from 2000 to 2006 and the rest were mela-
noma cases recruited for a study of melanoma on nonsun-
exposed sites.21 In Spain, 1,141 (52.24%) melanoma cases
from wide catchment areas who had SLN biopsy were
recruited from two University Hospitals in Barcelona and
Valencia from 1996 to 2013.
Clinical data
Of the 2,184 melanoma cases, 1,180 (54%) were females. The
median age at diagnosis was 53 years (range, 20–82). The site
of primary melanoma, when available (missing, 150), was
head and neck in 252 (12.4%), trunk in 828 (40.7%) and
limbs in 954 (46.9%). Overall mean Breslow thickness was
2.27 mm (SD, 62.21; median, 1.5 mm). The mean thickness
of United Kingdom cases was 2.086 0.05 mm (median, 1.3)
compared to 2.526 0.06 mm (median, 1.7) in Spain
(p< 0.001). Ulceration of primary melanoma was present in
495 of lesions (30.6%, 566 data missing). Ulcerated melano-
mas were significantly thicker than not ulcerated (3.916 0.14
vs. 1.766 0.05 mm, p5 0.001) and were more common in
older people (22.2% in <50 years old vs. 33.4% in 50 years
old, p< 0.001) (Table 1).
High mitotic rate (5 mitoses) (when available, 644 miss-
ing) was reported in 395 patients (25.6%). Higher mitotic
rate was associated with greater Breslow thickness (mean,
1.806 0.05 mm for <5 mitoses vs. 4.186 0.17 mm for 5
mitoses).
SLN was performed at staging in 1,289 patients (59%)
with 1,141 (88.5%) from Spain, whereas the remaining 148
patients (11.5%) were from United Kingdom. In total, 295
patients (22.9%) had a positive SNB status. Sentinel node
biopsy was not performed in 41% of the whole melanoma
cohort. These patients mainly came from United Kingdom
where sentinel node biopsy is less frequently performed com-
pared to Spain or they did not meet the inclusion criteria or
declined. There was a nonsignificant protective role of high
mole count on SLN status (p5 0.74). SLN status was not
associated with age or sex in our study. However, SLN status
was significantly associated with thicker tumors, ulceration
and mitotic rate (Table 2).
Correlations of melanoma prognostic factors
with nevus counts
In all, 684 (31.3%) melanoma cases had high nevus counts
(defined as [mt]50 nevi). The results are summarized in
Table 1. Age was inversely and highly correlated with high
nevus counts as expected (odds ratio [OR], 0.96; p< 0.001).
Male sex was associated with high nevus counts when age
was adjusted (OR5 1.22, p5 0.04). Breslow thickness was
inversely correlated with high nevus counts (OR5 0.89,
p< 0.001) as well as ulceration (OR5 0.74, p5 0.02) when
adjusted for age. Mitotic rate was not associated with high
nevus counts when adjusted for age (OR5 0.89, p5 0.39).
Trunk melanoma was the site most commonly associated
with high nevus counts in both sexes (females OR =1 .94,
p5 0.02; males OR5 1.71 p5 0.01).
Survival and nevus counts
Of the total of 2,184 patients, 283 (12.9%) died during the
followup. Median followup was 6.56 years (range, 0.21–
12.13). Univariable analyses showed that the known prognos-
tic factors of age, Breslow thickness, sex, site of the primary,
microscopic ulceration, mitotic rate and SLN status affected
the survival (Table 3). The patients with trunk and limb mel-
anoma had a better prognosis compared to head and neck
tumors. The Kaplan–Meier estimates for DSS showed a sig-
nificantly different survival between those with high versus
low nevus counts versus those with fewer nevi: DSS of 91.16
versus 86.4% at 5 years (p< 0.001) and 87.18 versus 79% at
10 years (p< 0.0001) (Fig. 1). The HR for melanoma death
in univariable analyses for high nevus count compared to
low nevus count in 2,133 patients was 0.47 (CI5 0.24–0.93,
p5 0.02). Univariate analyses showed that the known
prognostic factors of age, Breslow thickness, sex, site of the
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primary, microscopic ulceration, mitotic rate and SLN status
affected the survival (Table 3). In the univariate analyses,
nevus counts also improved the survival.
This difference in survival according to nevus counts was
maintained in multivariable analyses after the adjustment for
age, sex, Breslow thickness, ulceration, mitotic rate, site of
primary and country source (adjusted HR5 0.43; CI5 0.21–
0.89 and p5 0.02) (Table 3). Older age, increased Breslow
thickness, high mitotic count, site of primary on trunk as
well as positive SLN maintained an unfavorable prognostic
association for DSS in multivariable analyses (Table 3).
SLN positivity was slightly higher in cases with an excess
of nevi but once adjusted for all other melanoma prognostic
factors, this did not reach statistical significance. However,
SLN status was significantly associated with Breslow thick-
ness, ulceration and mitotic rate as reported before (Table 2).
Patients with higher nevus counts seem to receive more fre-
quently SLN biopsy. This could, in part, be explained by age
as better prognostic factors with thinner tumors are more
common in younger individuals. In fact, the association
between being offered a SLN biopsy and high nevus count
appeared to be mainly owing to the fact that United King-
dom had the highest percentage of individuals in the high
nevus count category and the lowest rates of sentinel node
biopsy which affected this association. However, the rate of
SNB positivity was similar across the three cohorts. High
nevus counts maintained a favorable prognostic role in the
positive SLN subgroup (n5 174) with an HR of 0.22
(CI5 0.08–0.60) once adjusted for all prognostic factors (Fig.
2 and Table 4).
Discussion
Our study shows, for the first time, that having high number
of melanocytic nevi at melanoma diagnosis is an independent
predictor of better DSS and this protective effect was also
observed in patients who have positive sentinel nodes. Mela-
noma cases with a high nevus count showed a reduction of
57% in melanoma-specific mortality (HR5 0.43, CI5 0.21–
0.89) compared to those with low nevus count after all
adjustments. High nevus count is a strong predictive risk
Table 1. Association between nevus number (high vs. low) and melanoma characteristics (p-values based on v2 test, Wilcoxon–Mann–
Whitney and t-test)
Low nevus count High nevus count Total p-Value
Countries United Kingdom 627 (60.1%) 416 (39.9%) 1,041 <0.0011
Spain 873 (76.5%) 268 (23.5%) 1,141
Sex Female 814 (69.3%) 361 (30.7%) 1,175 0.5661
Male 682 (68.1%) 319 (31.9%) 1,001
Age (years) Median 57 (20–84) 48.3 (20–76) <0.0012
Age categorical (years)‘ <50 541 (59.4%) 369 (40.5%) 910 <0.0011
50 937 (75%) 313 (25%) 1,250
Ulceration No 779 (69.4%) 344 (30.6%) 1,123 0.0011
Yes 382 (77.2%) 113 (22.8%) 495
Breslow thickness (mm) 2.4560.06 1.8660.07 <0.0013
Breslow thickness grouped
using AJCC
T1 364 (62.7%) 216 (37.2%) 580 <0.001
T2 531 (65.1%) 284 (34.8%) 815
T3 344 (75.1%) 114 (24.9%) 458
T4 227 (79.6%) 58 (20.3%) 285
Mitotic rate <5 784 (68.5%) 361 (31.5%) 1,145 0.051
5 291 (76.7%) 104 (26.3%) 395
Site of primary Head and neck 196 (77.8%) 56 (22.2%) 252 <0.0011
Trunk 528 (63.7%) 300 (36.2%) 828
Limbs 660 (69.2%) 294 (30.8%) 954
SLN performed No 531 (59.3%) 364 (40.7%) 895 <0.0011
Yes 969 (75.2%) 320 (24.8%) 1,289
SLN status Negative 745 (74.9%) 249 (25.0%) 994 0.7321
Positive 224 (75.9%) 71 (24.0%) 295
1p-Value calculated using Pearson’s v2d test.
2p-Value calculated with Wilcoxon–Mann–Whitney test.
3p-Value calculated using t-test.
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factor for cutaneous melanoma.2–4,27 Nevi involute with age,
a process which is likely to be, in part, genetically driven.28,29
The improved survival in melanoma cases with high nevus
counts raises the possibility that the genetic determinants of
nevi number may be associated with biological differences in
melanoma tumors.
A potential weakness of our study is that the analyses
were carried out in three different melanoma cohorts from
the United Kingdom and Spain. The fact that the three cen-
ters had slightly different inclusion criteria for entry into the
respective melanoma cohort with only the United Kingdom
study being population-based, whereas Valencia and Barce-
lona were retrospective studies from large melanoma second-
ary and tertiary referral centers were addressed at least, in
part, by adjusting for all melanoma prognostic factors. The
distribution of these prognostic factors proved to be very
similar between the three centers with slightly thicker tumors
in Spain, owing to the inclusion criteria, as patients being
offered only SLN biopsy were included in the Spanish mela-
noma cohorts. The differences regarding the recommenda-
tions for SLN biopsy in the three different centers were also
a weakness with United Kingdom having a very low rate of
SLN biopsy. However, we adjusted for the source of the
cohort. Furthermore, as there is no evidence that having SLN
biopsy affects survival, the differences in SLNB practices
between UK and Spain are unlikely to have been an issue for
the survival analyses.30 There is no reason to speculate that
nevus counts may be altering the decision of a clinician to
offer sentinel node biopsy or the patient to accept the proce-
dure apart from age.
Nevus cell senescence may occur, at least in part, because
of telomere attrition as the telomere unit has been linked to
both high nevus number and melanoma risk.6,16,18,31,32 Telo-
mere attrition is reported to trigger the induction of tumor
suppressor proteins including p16 (INK4a) and many other
cell-cycle genes.10,11 Age did not impact on SLN status in our
study in contrast with the results of Balch et al.33 but we did
not have so many cases in the extreme of ages as seen in the
Balch series (such as under 20 years or older than 80 years).
Breslow thickness, truncal tumors and mitotic rate main-
tained unfavorable prognostic roles in Stage III as reported
earlier.34–37
Higher number of nevi was associated with more favor-
able prognostic factors in terms of tumor characteristics such
as thinner melanoma, less ulceration and fewer mitoses.
Higher numbers of nevi were more frequent in participants
with trunk melanoma, confirming data from a previous
large-pooled analysis of melanoma case–control studies.27
However, the protective effect of higher nevus counts on
Table 2. Multivariable logistic regression looking at all melanoma
prognostic factors according to SLN status: positive versus negative
(N5724)
SLN status OR p-Value 95% CI
Nevus count >50 1.20 0.43 0.76–1.88
Age Linear 1.00 0.81 0.99–1.01
Breslow
thickness (mm)
Linear 1.11 0.002 1.04–1.19
Sex (Male vs. female) 1.13 0.524 0.78–1.64
Site of primary Head and neck 1
Trunk 1.79 0.07 0.95–3.37
Limbs 1.52 0.21 0.79–2.91
The presence
of ulceration
(Yes vs. no) 1.82 0.003 1.23–2.70
Tumor mitotic
rate
(5 vs. <5) 1.55 0.03 1.03–2.33
Countries United Kingdom 1
Spain 0.81 0.45 0.47–1.40
Table 3. Univariable and multivariable cox analyses on DSS (n5724)
Univariable Multivariable
HR p-Value 95% CI HR p-Value 95% CI
Nevus count >50 0.47 0.03 0.24–0.93 0.43 0.02 0.21–0.89
Age Linear 1.03 <0.001 1.02–1.05 1.02 0.02 1.00–1.04
Breslow thickness (mm) 1.15 <0.001 1.10–1.19 1.07 0.02 1.01–1.14
Sex (Male vs. female) 1.76 0.02 1.10–2.81 1.60 0.07 0.96–2.65
Site of primary Head and neck 1 1
Trunk 0.31 <0.001 0.16–0.56 0.23 <0.001 0.12–0.44
Limbs 0.45 0.01 0.25–0.81 0.46 0.01 0.25–0.84
The presence of ulceration (Yes vs. no) 2.90 <0.001 1.85–4.53 1.30 0.29 0.79–2.14
Tumor mitotic rate (5 vs. <5) 4.14 0.000 2.62–6.53 3.00 0.000 1.81–4.97
SLN status Positive vs. negative 4.41 <0.001 3.38–5.75 3.72 <0.001 2.29–6.04
Countries United Kingdom 1 1
Spain 1.20 0.53 0.67–2.14 1.10 0.76 0.59–2.04
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survival was independent of these well-established melanoma
prognostic factors as the association remained after all adjust-
ments. Other factors may possibly affect the number of nevi
and may need to be further investigated. For example, a his-
tory of eczema has been associated with lower nevus counts,
possibly because of increased immune activation in the
skin.38 However, all melanoma survival analyses reported in
the literature have, so far, not collected any data on dermato-
sis and hence this cannot be checked for our study. The so-
called divergent aetiology hypothesis which has been explored
by many groups39–41 is that melanoma may arise through at
least two different phenotypic pathways: one in younger peo-
ple, associated with melanocyte proliferation and thus high
nevus count, more likely to occur on the trunk, the other
with a more frequent localization on the head and neck in
elderly people without nevi but more sun damage. The
improved survival in patients with high nevus counts sup-
ports the view that the biology of different types of mela-
noma in terms of cutaneous phenotypic risk factors may
impact on the survival.
The explanation for a protective effect of an excess of nevi
(and implied longer telomeres) on melanoma survival is not
clear but may reflect biological differences driven by genes
involved in nevogenesis or inherited variations in host
responses to the tumor which may be greater in the presence
of many nevi. We speculate that as high nevus count is asso-
ciated with longer white cell telomeres, this might be a
marker of delayed senescence of cells of many other lineages
with a possible influence on the immune system as well.6,42
Hence, one hypothesis is that longer telomeres in immune
cells from patients with many nevi might, therefore, be bene-
ficial. The immune system plays a fundamental role in mela-
noma progression. Older age at diagnosis is an independent
unfavorable prognostic factor even after adjusting for all
other melanoma prognostic factors.43,44 The age effect on
survival might be owing to the differences in the aggressive-
ness of the tumor and/or altered host response to the disease
as well as changes in lymphatic flow, comorbidities, or a
combination of these factors. The immune system is suscepti-
ble to age-related changes especially in the CD4 compartment
with an expansion of CD4 Tregs with age.45 Telomere length
and telomerase activity also have effects on the immune sys-
tem with the expansion of CD41 and CD251 regulatory T
cells with shorter telomeres.46 A second hypothesis is that the
beneficial effect of nevus number on survival may reflect a
modifying effect on tumor cell telomeres. A direct effect of
white cell telomere length on melanoma survival has not
been clearly proven. Although it has been suggested that
shorter white cell telomere length could be associated with a
reduced melanoma survival which supports the role of telo-
meres in melanoma survival and in the same direction as our
Figure 1. Kaplan–Meier DSS estimates for nevus counts stratified
into high nevus counts (>50 mol) and low nevus counts
(50 mol) in three cohorts from Leeds, Valencia and Barcelona. A
significant difference in survival was observed between the high
nevus count and the low nevus count group (log-rank test;
p<0.001).
Figure 2. Kaplan–Meier survival estimates for nevus count and SLN
status (log-rank test; p<0.001).
Table 4. Multivariable Cox analyses on DSS in SLN-positive group
only (n5174)
HR p-Value 95% CI
Nevus count >50 0.22 0.003 0.08–0.60
Age 1.01 0.44 0.99–1.03
Breslow
thickness (mm)
1.09 0.04 1.00–1.19
Sex (Male vs. female) 1.54 0.231 0.76–3.17
Site of primary Head and neck 1
Trunk 0.14 <0.001 0.05–0.39
Limbs 0.48 0.106 0.19–1.17
The presence
of ulceration
(Yes vs. no) 0.75 0.428 0.37–1.51
Tumor mitotic rate (5 vs. <5) 3.92 <0.001 1.84–8.35
Countries United Kingdom 1
Spain 0.78 0.571 0.32–1.86
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data.47 The effect of telomere length has already been reported
in colon cancer as accelerated telomere erosion is associated
with a worse survival,48 a phenomenon reported to be associ-
ated with a decline of immune functions believed to be caused
by a shortening of telomeres.49 More recent data suggest that
somatic alterations in the TERT gene are associated with a
worse melanoma prognosis, and hence these results may
appear to conflict with our results. It is, however, unknown
whether these TERT mutations present in the tumor lead to
longer white cell telomere length in these studies.32,50,51
High nevus counts, while increasing melanoma risk, appear to
have a favorable independent prognostic significance in patients
with melanoma implying biological differences in melanoma
tumors explained by genetic or environmental factors linked to
high nevus counts which could be mediated by telomere biology
and/or immune responses. This has implications for melanoma
biology and clinicians should be encouraged to record nevus
counts in patients with melanoma in clinical practice to assess the
role of the nevus phenotype in melanoma survival as well as
responses to immunologic and gene-targeted treatments.
References
1. Swerdlow AJ, Green A. Melanocytic nevi and
melanoma: an epidemiological perspective. Br J
Dermatol 1987;117:137–46.
2. Bataille V, Bishop JA, Sasieni P, et al. Risk of
cutaneous melanoma in relation to the numbers,
types and sites of naevi: a case-control study. Br J
Cancer 1996;73:1605–11.
3. Gandini S, Sera F, Cattaruzza M, et al. Meta-
analysis of risk factors for cutaneous melanoma:
I. Common and atypical naevi. Eur J Cancer
2005;41:28–44.
4. Ballester I, Oliver V, Ba~nuls J, et al. Multicenter
case-control study of risk factors for cutaneous
melanoma in Valencia, Spain. Actas Dermosifi-
liogr 2012;103:790–7.
5. Usher-Smith JA, Emery J, Kassianos AP, et al.
Risk prediction models for melanoma: a system-
atic review. Cancer Epidemiol Biomarkers Prev
2014;23:1450–63.
6. Bataille V, Kato BS, Falchi M, et al. Naevus size
and number are associated with telomere length
and represent potential markers of a decreased
senescence in vivo. Cancer Epidemiol Biomarkers
Prev 2007;16:1499–1502.
7. Newton Bishop JA, Harland M, Bishop DT. The
genetics of melanoma: the UK experience. Clin
Exp Dermatol 1998;23:158–61.
8. Newton JA, Bataille V, Griffiths K, et al. How
common is the atypical mole syndrome pheno-
type in apparently sporadic melanoma? J Am
Acad Dermatol 1993;29:989–96.
9. Burke LS, Hyland PL, Pfeiffer RM, et al. Telo-
mere length and the risk of cutaneous malignant
melanoma in melanoma-prone families with and
without CDKN2A mutations. PLoS One 2013;8:
e71121.
10. Michaloglou C, Vredeveld LC, Soengas MS,et al.
BRAFE600-associated senescence-like cell cycle
arrest of human naevi. Nature 2005;436:720–4.
11. Peeper DS. Oncogene-induced senescence and
melanoma: where do we stand? Pigment Cell Mel-
anoma Res 2011;24:1107–11.
12. Nan H, Du M, De Vivo I, et al. Shorter telomeres
associate with a reduced risk of melanoma devel-
opment. Cancer Res 2011;71:6758–63.
13. Han J, Qureshi AA, Prescott J, et al. A prospec-
tive study of telomere length and the risk of skin
cancer. J Invest Dermatol 2009;129:415–21.
14. Bodelon C, Pfeiffer RM, Bollati V, et al. On the
interplay of telomeres, naevi and the risk of mela-
noma. PLoS One 2012;7:e52466.
15. Duffy DL, Iles MM, Glass D, et al. IRF4 variants
have age-specific effects on naevus count and pre-
dispose to melanoma. Am J Hum Genet 2010;87:
6–16.
16. Horn S, Figl A, Rachakonda PS, et al. TERT pro-
moter mutations in familial and sporadic mela-
noma. Science 2013;339:959–61.
17. Huang FW, Hodis E, Xu MJ, et al. Highly recur-
rent TERT promoter mutations in human mela-
noma. Science 2013;6122:957–9.
18. Robles-Espinoza CD, Harland M, Ramsay AJ,
et al. POT1 loss-of-function variants predispose
to familial melanoma. Nat Genet 2014;46:478–81.
19. Shi J, Yang XR, Ballew B, et al. Rare missense
variants in pot1 predispose to familial cutaneous
malignant melanoma. Nat Genet 2014;46:482–6.
20. Iles MM, Bishop DT, Taylor JC, et al. The effect
on melanoma risk of genes previously associated
with telomere length J Natl Cancer Inst 2014;106:
dju267.
21. Newton-Bishop JA, Chang YM, Elliott F, et al.
Relationship between sun exposure and mela-
noma risk for tumours in different body sites in
a large case-control study in a temperate climate.
Eur J Cancer 2011;47:732–41.
22. Messeguer F, Agustı-Mejıas A, Traves V, et al.
Mitotic rate and subcutaneous involvement are
prognostic factors for survival after recurrence in
patients with only locoregional skin metastasis as
the first site of recurrence from cutaneous mela-
noma. J Eur Acad Dermatol Venereol 2013;27:
436–41.
23. Vidal-Sicart S, Pons F, Puig S, et al. Identification
of the sentinel lymph node in patients with malig-
nant melanoma: what are the reasons for mistakes?
Eur J Nucl Med Mol Imaging 2003;30:362–6.
24. Cuellar FA, Vilalta A, Rull R, et al. Small cell
melanoma and ulceration as predictors of positive
sentinel lymph node in malignant melanoma
patients. Melanoma Res 2004;14:277–82.
25. Puig S, Marcoval J, Paradelo C, et al. Melanoma
incidence increases in the elderly of catalonia but
not in the younger population: effect of preven-
tion or consequence of immigration? Acta Derm
Venereol 2014; doi: 10.2340/00015555-1997.
[Epub ahead of print]
26. Vecchiato A, Pasquali S, Menin C, et al. Histo-
pathological characteristics of subsequent melano-
mas in patients with multiple primary
melanomas. J Eur Acad Dermatol Venereol 2014;
28:58–64.
27. Chang YM, Barrett JH, Bishop DT, et al. Sun
exposure and melanoma risk at different lati-
tudes: a pooled analysis of 5700 cases and 7216
controls. Int J Epidemiol 2009;38:814–30.
28. Bataille V, Snieder H, MacGregor AJ, et al.
Genetics of risk factors for melanoma: an adult
twin study of naevi and freckles. J Natl Cancer
Inst 2000;92:457–63.
29. Wachsmuth RC, Gaut RM, Barrett JH, et al. Her-
itability and gene-environment interactions for
melanocytic naevus density examined in a U.K.
adolescent twin study. J Invest Dermatol 2001;
117:348–52.
30. Morton DL, Thompson JF, Cochran AJ, et al.
Sentinel-node biopsy or nodal observation in
melanoma. N Engl J Med. 2006;355:1307–17.
31. Law MH, Montgomery GW, Brown KM, et al.
Meta-analysis combining new and existing data
sets confirms that the TERT-CLPTM1L locus
influences melanoma risk. J Invest Dermatol
2012;132:485–7.
32. Griewank KG, Murali R, Puig-Butille JA, et al.
TERT promoter mutation status is an independ-
ent prognostic factor in cutaneous melanoma.
J Natl Cancer Inst 2014;106:dju246.
33. Balch CM, Thompson JF, Gershenwald JE, et al.
Age as a predictor of sentinel node metastasis
among patients with localized melanoma: an
inverse correlation of melanoma mortality and
incidence of sentinel node metastasis among
young and old patients. Ann Surg Oncol 2014;21:
1075–81.
34. Quaglino P, Ribero S, Osella-Abate S, et al. Clin-
ico-pathologic features of primary melanoma and
sentinel lymph node predictive for non-sentinel
lymph node involvement and overall survival in
melanoma patients: a single centre observational
cohort study. Surg Oncol 2010;20:259–64.
35. Thompson JF, Soong SJ, Balch CM, et al. Prog-
nostic significance of mitotic rate in localized pri-
mary cutaneous melanoma: an analysis of
patients in the multi-institutional American Joint
Committee on Cancer melanoma staging data-
base. J Clin Oncol 2011;29:2199–205.
36. Morton DL, Thompson JF, Cochran AJ, et al.
Final trial report of sentinel-node biopsy versus
nodal observation in melanoma. N Engl J Med
2014;370:599–609.
37. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic
rate and younger age are predictors of sentinel
lymph node positivity: lessons learned from the
generation of a probabilistic model. Ann Surg
Oncol 2004;11:247–58.
38. Kallas M, Rosdahl I, Fredriksson M, et al. Fre-
quency and distribution pattern of melanocytic
naevi in Estonian children and the influence of
atopic dermatitis. J Eur Acad Dermatol Venereol
2006;20:143–8.
39. Bataille V, Grulich A, Sasieni P, et al. The associ-
ation between naevi and melanoma in popula-
tions with different levels of sun exposure: a joint
case-control study of melanoma in the UK and
Australia. Br J Cancer 1998;77:505–10.
E
pi
de
m
io
lo
gy
Ribero et al. 1697
Int. J. Cancer: 137, 1691–1698 (2015)VC 2015 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
40. Whiteman DC, Watt P, Purdie DM, et al. Mela-
nocytic naevi, solar keratoses, and divergent path-
ways to cutaneous melanoma. J Natl Cancer Inst
2003;95:806–812.
41. Olsen CM, Zens MS, Stukel TA, et al. Naevus
density and melanoma risk in women: a pooled
analysis to test the divergent pathway hypothesis.
Int J Cancer 2009;15;124:937–44
42. Ribero S, Glass D, Aviv A, et al. Height and bone
mineral density are associated with naevus count
supporting the importance of growth in mela-
noma susceptibility. PLoS One 2015;10:e0116863.
43. Lasithiotakis K, Leiter U, Meier F, et al. Age and
sex are significant independent predictors of sur-
vival in primary cutaneous melanoma. Cancer
2008;112:1795–804.
44. Balch CM, Soong SJ, Gershenwald JE, et al. Age
as a prognostic factor in patients with localized
melanoma and regional metastases. Ann Surg
Oncol 2013;20:3961–8.
45. Jagger A, Shimojima Y, Goronzy JJ, et al. Regula-
tory T cells and the immune aging process: a
mini-review. Gerontology 2014;60:130–7.
46. Wolf D, Rumpold H, Koppelst€atter C, et al.
Telomere length of in vivo expanded cd4(1)cd25
(1) regulatory T-cells is preserved in cancer
patients. Cancer Immunol Immunother 2006;55:
1198–208.
47. Weischer M, Nordestgaard BG, Cawthon RM,
et al. Short telomere length, cancer survival, and
cancer risk in 47102 individuals. J Natl Cancer
Inst 2013;105:459–68.
48. Chen Y, Qu F, He X, et al. Short leukocyte
telomere length predicts poor prognosis and
indicates altered immune functions in colo-
rectal cancer patients. Ann Oncol 2014;25:
869–76.
49. Iancu EM, Speiser DE, Rufer N. Assessing ageing
of individual T lymphocytes: mission impossible?
Mech Ageing Dev 2008;129:67–78.
50. Diaz A, Puig-Butille JA, Mu~noz C, et al. TERT
gene amplification is associated with poor out-
come in acral lentiginous melanoma. J Am Acad
Dermatol 2014;71:839–41.
51. Heidenreich B, Nagore E, Rachakonda PS, et al.
Telomerase reverse transcriptase promoter
mutations in primary cutaneous melanoma. Nat
Commun 2014;5:3401
E
pi
de
m
io
lo
gy
1698 Nevus counts impact on melanoma survival
Int. J. Cancer: 137, 1691–1698 (2015)VC 2015 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
